Astrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington's disease

GLIA

Volumn 64, Issue 11, 2016, Pages 1841-1856

  Meunier, Cécile ^a   Merienne, Nicolas ^b   Jollé, Charlotte ^a   Déglon, Nicole ^b   Pellerin, Luc ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

adenoassociated viral vectors; glia; mouse model; polyglutamine expansion; striatum

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; HUNTINGTIN; PHOSPHOPROTEIN DARPP 32;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BASAL GANGLION; BODY WEIGHT; CELL POPULATION; CONTROLLED STUDY; HUNTINGTON CHOREA; LOCOMOTION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SYMPTOMATOLOGY;

EID: 84990861406     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.23022     Document Type: Article

References (51)

1. Acuna AI, Esparza M, Kramm C, Beltran FA, Parra AV, Cepeda C, Toro CA, Vidal RL Hetz C, Concha II, Brauchi S, Levine MS, Castro MA. 2013. A failure in energy metabolism and antioxidant uptake precede symptoms of Huntington's disease in mice. Nat Commun 4:2917.
2. Ali NJ, Levine MS. 2006. Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington's disease. Dev Neurosci 28:230–238.
3. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. 2004. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805–810.
4. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc 57:289.
5. Blank T, Nijholt I, Teichert U, Kugler H, Behrsing H, Fienberg A, Greengard P, Spiess J. 1997. The phosphoprotein DARPP-32 mediates cAMP-dependent potentiation of striatal N-methyl-D-aspartate responses. Proc Natl Acad Sci U S A 94:14859–14864.
6. Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. 2009. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A 106:22480–22485.
7. Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. 2015. Treating the whole body in Huntington's disease. Lancet Neurol 14:1135–1142.
8. Chung WS, Welsh CA, Barres BA, Stevens B. 2015. Do glia drive synaptic and cognitive impairment in disease? Nat Neurosci 18:1539–1545.
9. Colin A, Faideau M, Dufour N, Auregan G, Hassig R, Andrieu T, Brouillet E, Hantraye P, Bonvento G, Deglon N. 2009. Engineered lentiviral vector targeting astrocytes in vivo. Glia 57:667–679.
10. de Almeida LP, Ross CA, Zala D, Aebischer P, Deglon N. 2002. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 22:3473–3483.
11. de Leeuw B, Su M, ter Horst M, Iwata S, Rodijk M, Hoeben RC, Messing A, Smitt PS, Brenner M. 2006. Increased glia-specific transgene expression with glial fibrillary acidic protein promoters containing multiple enhancer elements. J Neurosci Res 83:744–753.
12. Dvorzhak A, Vagner T, Kirmse K, Grantyn R. 2016. Functional indicators of glutamate transport in single striatal astrocytes and the influence of Kir4.1 in normal and Huntington mice. J Neurosci 36:4959–4975.
13. Estrada Sanchez AM, Mejia-Toiber J, Massieu L. 2008. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 39:265–276.
14. Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N, Guillermier M, Brouillet E, Hantraye P, Déglon N, Ferrante RJ, Bonvento G. 2010. In vivo expression of polyglutamine-expanded Huntingtin by mouse striatal astrocytes impairs glutamate transport: A correlation with Huntington's disease subjects. Hum Mol Genet 19:3053–3067.
15. Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D. 2008. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 16:947–956.
16. Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD, Van Eldik LJ, Norris CM. 2012. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci 32:16129–16140.
17. Fusco F, Chen Q, Lamoreaux W, Figueredo-Cardenas G, Jiao Y, Coffman J, Surmeier DJ, Honig MG, Carlock LR, Reiner A. 1999. Cellular localization of Huntingtin in striatal and cortical neurons in rats: Lack of correlation with neuronal vulnerability in Huntington's disease. J Neurosci 19:1189–1202.
18. Glisic D, Lehmann C, Figiel M, Odemis V, Lindner R, Engele J. 2012. A novel cross-talk between endothelin and ErbB receptors controlling glutamate transporter expression in astrocytes. J Neurochem 122:844–855.
19. Glorioso JC, Cohen JB, Carlisle DL, Munoz-Sanjuan I, Friedlander RM. 2015. Moving toward a gene therapy for Huntington's disease. Gene Ther 22:931–933.
20. Greengard P, Allen PB, Nairn AC. 1999. Beyond the dopamine receptor: The DARPP-32/protein phosphatase-1 cascade. Neuron 23:435–447.
21. Guo Z, Rudow G, Pletnikova O, Codispoti KE, Orr BA, Crain BJ, Duan W, Margolis RL, Rosenblatt A, Ross CA, Troncoso JC. 2012. Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Mov Disord 27:1379–1386.
22. Heiman M, Schaefer A, Gong S, Peterson JD, Day M, Ramsey KE, Suarez-Farinas M, Schwarz C, Stephan DA, Surmeier DJ, Greengard P, Heintz N. 2008. A translational profiling approach for the molecular characterization of CNS cell types. Cell 135:738−748.
23. Hult S, Soylu R, Bjorklund T, Belgardt BF, Mauer J, Bruning JC, Kirik D, Petersen A. 2011. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab 13:428–439.
24. Klein RL, Dayton RD, Tatom JB, Henderson KM, Henning PP. 2008. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: Effects of serotype, promoter and purification method. Mol Ther 16:89–96.
25. Kretzschmar D, Tschape J, Bettencourt Da Cruz A, Asan E, Poeck B, Strauss R, Pflugfelder GO. 2005. Glial and neuronal expression of polyglutamine proteins induce behavioral changes and aggregate formation in Drosophila. Glia 49:59–72.
26. Lievens J-C, Bernal F, Forni C Mahy N, Kerkerian-Le Goff L, 2000. Characterization of striatal lesions produced by glutamate uptake alteration: Cell death, reactive gliosis, and changes in GLT1 and GADD45 mRNAExpression. Glia 29:222–232.
27. Ma L, Morton AJ, Nicholson LF. 2003. Microglia density decreases with age in a mouse model of Huntington's disease. Glia 43:274–280.
28. Ma L, Piirainen S, Kulesskaya N, Rauvala H, Tian L. 2015. Association of brain immune genes with social behavior of inbred mouse strains. J Neuroinflammation 12:75
29. Merienne N, Delzor A, Viret A, Dufour N, Rey M, Hantraye P, Deglon N. 2015. Gene transfer engineering for astrocyte-specific silencing in the CNS. Gene Ther 22:830–839.
30. Merienne N, Le Douce J, Faivre E, Deglon N, Bonvento G. 2013. Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors. Front Cell Neurosci 7:106
31. Moore CB, Guthrie EH, Huang MT, Taxman DJ. 2010. Short hairpin RNA (shRNA): Design, delivery, and assessment of gene knockdown. Methods Mol Biol 629:141–158.
32. Morales I, Rodriguez M. 2012. Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity. Glia 60:1481–1494.
33. Phan J, Hickey MA, Zhang P, Chesselet MF, Reue K. 2009. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum Mol Genet 18:1006–1016.
34. Pla P, Orvoen S, Saudou F, David DJ, Humbert S. 2014. Mood disorders in Huntington's disease: From behavior to cellular and molecular mechanisms. Front Behav Neurosci 8:135-
35. Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, D'Ambola J, Hou Z, Liang Y, Poirier MA, Hirschhorn RR, Graham R, Hayden MR, Cole RN, Ross CA. 2009. Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem 284:10855–10867.
36. Roos RA. 2010. Huntington's disease: A clinical review. Orphanet J Rare Dis 5:40-
37. Roth A, Kyzar E, Cachat J, Stewart AM, Green J, Gaikwad S, O'Leary TP, Tabakoff B, Brown RE, Kalueff AV. 2013. Potential translational targets revealed by linking mouse grooming behavioral phenotypes to gene expression using public databases. Prog Neuropsychopharmacol Biol Psychiatry 40:312–325.
38. Sahl SJ, Weiss LE, Duim WC, Frydman J, Moerner WE. 2012. Cellular inclusion bodies of mutant huntingtin exon 1 obscure small fibrillar aggregate species. Sci Rep 2:895-
39. The Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Hutnington's disease chromosomes. Cell 72:971–983.
40. Tong X, Ao Y, Faas GC, Nwaobi SE, Xu J, Haustein MD, Anderson MA, Mody I, Olsen ML, Sofroniew MV, Khakh BS. 2014. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat Neurosci 17:694–703.
41. Tydlacka S, Wang CE, Wang X, Li S, Li XJ. 2008. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci 28:13285–13295.
42. van der Burg JM, Bjorkqvist M, Brundin P. 2009. Beyond the brain: Widespread pathology in Huntington's disease. Lancet Neurol 8:765−774.
43. Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR. 2006. Body weight is modulated by levels of full-length huntingtin. Hum Mol Genet 15:1513–1523.
44. Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL. 2004. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 14:95–104.
45. Venuto CS, McGarry A, Ma Q, Kieburtz K. 2012. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 27:31–41.
46. Wise RA. 2006. Role of brain dopamine in food reward and reinforcement. Philos Trans R Soc Lond B Biol Sci 361:1149–1158.
47. Wright AV, Nunez JK, Doudna JA. 2016. Biology and applications of CRISPR systems: Harnessing nature's toolbox for genome engineering. Cell 164:29–44.
48. Yang Y, Gozen O, Vidensky S, Robinson MB, Rothstein JD. 2010. Epigenetic regulation of neuron-dependent induction of astroglial synaptic protein GLT1. Glia 58:277–286.
49. Yang Y, Gozen O, Watkins A, Lorenzini I, Lepore A, Gao Y, Vidensky S, Brennan J, Poulsen D, Won Park J, Li Jeon N, Robinson MB, Rothstein JD. 2009. Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron 61:880–894.
50. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ. 2014. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34:11929–11947.
51. Zuccato C, Valenza M, Cattaneo E. 2010. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90:905–981.